Sunday, September 30, 2012

The Prostate: Genetic Marker in the News

by Margaret Aranda, MD, Ph.D.

Yesterday I met Karim Kadir, M.D., Ph.D., who has studied, lectured, and been dedicated to assisting in the early diagopsis of severe prostate cancer.  He and his Team have authored many papers, researched the field, reviewed the literature, written National Institues of Health (NIH) Grants, and are now novel scientists in their own right, in the forefront of prostate cancer markers.

Prostate cancer is probably "the" most "genetic" cancer of all time and this evolving, simple test has the potential to revolutionize the future of prostate health care, in my opinion.  One of six males will end up with prostate cancer, and the old stand-by, current test, the prostate-specific antigen (PSA), is well-known for being neither sensitive nor specific to determine whether prostate cancer has occurred. 

Through single polymerase nuceotide and genetic mapping techniques, it seems that Kadir et al have the first biological marker that can determine, from a genetic basis, whether severe prostate cancer will be likely to occur in a man.  This test may be performed from a single cheek swab on a male, even at birth or infancy.  This is possible because the DNA and the genetic makeup of a male is already determined at birth.

Perhaps two years in the making, keep your eyes out for this one.  What a robust marker this could be to determine who may have the genetically disposition for severe prostate cancer.


References:

1.  A. Karim Kadir, M.D., Ph.D. View Here

2.   Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk of prostate cancer.  Prostate 2011 March 1: 71(4):421-430.
View Article Here

3.  Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables on 5,895 prostate cancer patients. Prostate 20009 August 1: 69(11):1195-1205.
View Article Here

4. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic variation.  Prostate 2010 December 1: 70(16):1729-1738.
View Article Here

5. Curriculum Vitae, A. Karim Kadir, M.D., Ph. D. View CV Here






Medical Disclaimer: Nothing on this website is meant to diagnose, treat, or practice medicine. You must be seen in person by a physician for appropriate and individual medical treatment. If you have an emergency, call 9-1-1 in the USA.

Link Disclaimer: We are not responsible for any links that go outside of this website.

Full Disclosure: Margaret A. Ferrante, M.D.  is an Institute Physician with Cenegenics Medical Institute.  She receives no monetary compensation for hosting this website you are on, which is independent and not affiliated with Cenegenics. The information presented is for education and awareness.  Dr. Ferrante currently sees patients out of the Cenegenics office in Beverly Hills, CA. 
To book an appointment for a free Consultation, please email her at: mferrante@cenegenics.com










No comments:

Post a Comment